TRCT
CADL icon

Tower Research Capital (TRC)’s Candel Therapeutics CADL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.6K Buy
2,981
+1,102
+59% +$6K ﹤0.01% 3695
2025
Q4 		$10.6K Sell
1,879
-3,753
-67% -$20.2K ﹤0.01% 3735
2025
Q3 		$28.7K Sell
5,632
-3,976
-41% -$23K ﹤0.01% 2977
2025
Q2 		$48.6K Buy
9,608
+7,527
+362% +$38.7K ﹤0.01% 2993
2025
Q1 		$11.8K Buy
2,081
+624
+43% +$5.1K ﹤0.01% 3508
2024
Q4 		$12.6K Sell
1,457
-1,279
-47% -$7.56K ﹤0.01% 3598
2024
Q3 		$19K Buy
2,736
+1,484
+119% +$9.22K ﹤0.01% 3268
2024
Q2 		$7.76K Sell
1,252
-2,450
-66% -$18.4K ﹤0.01% 4428
2024
Q1 		$5.85K Sell
3,702
-3,031
-45% -$4.5K ﹤0.01% 4478
2023
Q4 		$9.9K Sell
6,733
-1,914
-22% -$1.86K ﹤0.01% 4331
2023
Q3 		$7.96K Buy
8,647
+385
+5% +$445 ﹤0.01% 4416
2023
Q2 		$10.4K Buy
8,262
+1,686
+26% +$2.49K ﹤0.01% 4126
2023
Q1 		$9K Sell
6,576
-638
-9% -$1.24K ﹤0.01% 4469
2022
Q4 		$13K Buy
7,214
+3,077
+74% +$6.09K ﹤0.01% 3582
2022
Q3 		$13K Buy
4,137
+2,918
+239% +$9.89K ﹤0.01% 4259
2022
Q2 		$4K Buy
1,219
+1,165
+2,157% +$4.67K ﹤0.01% 5175
2022
Q1 		$0 Buy
+54
New +$268 ﹤0.01% 6112

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tower Research Capital (TRC)'s CADL Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Candel Therapeutics (CADL) stake by 59% in Q1 2026, buying an estimated $6K and bringing the position to 2,981 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3695.

Tower Research Capital (TRC) first reported a position in CADL in Q1 2022 and has held it in 17 quarters since. The position peaked at $48.6K in Q2 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Tower Research Capital (TRC) held 2,981 shares of Candel Therapeutics worth $14.6K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,102 Candel Therapeutics shares in Q1 2026, an estimated $6K.
  • Candel Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3695 holding.
  • Tower Research Capital (TRC) first reported a position in Candel Therapeutics in Q1 2022 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Candel Therapeutics position peaked at $48.6K in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.